SGS
TCRT icon

Sterling Global Strategies’s Alaunos Therapeutics TCRT Stock Holding History

Sterling Global Strategies’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-7
Closed -$1.87K – 170
2018
Q4 		$1.87K Buy
+7
New +$2.77K 0.01% 210

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sterling Global Strategies's TCRT Position: Q1 2019 in Review

Sterling Global Strategies sold out of Alaunos Therapeutics (TCRT) in Q1 2019, closing a stake of 7 shares — an estimated $1.87K sold.

Sterling Global Strategies first reported a position in TCRT in Q4 2018 and held it in 1 quarter. The position peaked at $1.87K in Q4 2018. 124 funds tracked by Wall St. Rank hold TCRT as of Q1 2019.

  • Sterling Global Strategies reported no remaining Alaunos Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Sterling Global Strategies sold 7 Alaunos Therapeutics shares in Q1 2019, an estimated $1.87K.
  • Sterling Global Strategies first reported a position in Alaunos Therapeutics in Q4 2018 and held it in 1 quarter.
  • Sterling Global Strategies's Alaunos Therapeutics position peaked at $1.87K in Q4 2018.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2019.

Based on Sterling Global Strategies's 13F filing for Q1 2019, filed 15 May 2019.